Biora Historical Balance Sheet

BIOR Stock

USD 1.93 0.14 7.82%

Trend analysis of Biora Therapeutics balance sheet accounts such as Short Long Term Debt Total of 45.1 M, Other Current Liabilities of 35.5 M or Total Current Liabilities of 53.2 M provides information on Biora Therapeutics' total assets, liabilities, and equity, which is the actual value of Biora Therapeutics to its prevalent stockholders. By breaking down trends over time using Biora Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Biora Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Biora Therapeutics is a good buy for the upcoming year.

Biora Therapeutics Inventory

2.23 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biora Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Biora Stock, please use our How to Invest in Biora Therapeutics guide.

About Biora Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Biora Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Biora Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Biora Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Biora currently owns. An asset can also be divided into two categories, current and non-current.

Biora Therapeutics Balance Sheet Chart

At this time, Biora Therapeutics' Capital Stock is relatively stable compared to the past year. As of 11/28/2024, Non Current Liabilities Other is likely to grow to about 2.7 M, while Short and Long Term Debt Total is likely to drop slightly above 45.1 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Biora Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Biora Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Biora Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Biora Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Biora Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Biora Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biora Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Biora Stock, please use our How to Invest in Biora Therapeutics guide.At this time, Biora Therapeutics' Capital Stock is relatively stable compared to the past year. As of 11/28/2024, Non Current Liabilities Other is likely to grow to about 2.7 M, while Short and Long Term Debt Total is likely to drop slightly above 45.1 M.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	126.4M	127.8M	47.4M	45.1M
Total Assets	108.8M	53.5M	31.2M	29.7M

Short Long Term Debt Total Total Assets

Biora Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets	Other Stockholder Equity
Total Assets		0.4	-0.35	0.61	0.56	0.26	0.29	0.86	0.53	-0.36	0.76	0.9	0.8	0.75	-0.54	0.44	0.24	0.92	0.47	0.84	-0.92	0.02	0.04	0.8	0.1	-0.69
Short Long Term Debt Total	0.4		0.41	-0.32	-0.39	0.65	-0.58	0.02	-0.45	0.63	-0.19	0.34	0.74	-0.1	0.01	0.71	0.95	0.48	-0.16	0.38	-0.25	0.81	-0.62	0.19	0.87	0.29
Other Current Liab	-0.35	0.41		-0.43	-0.82	0.55	-0.78	-0.62	-0.9	0.47	-0.83	-0.31	0.19	-0.72	0.79	0.48	0.5	-0.17	-0.57	-0.53	0.64	0.67	-0.75	-0.41	0.78	0.85
Total Current Liabilities	0.61	-0.32	-0.43		0.55	0.06	0.37	0.78	0.77	-0.74	0.7	0.76	0.2	0.7	-0.36	0.03	-0.43	0.37	0.81	0.45	-0.59	-0.47	0.23	0.74	-0.4	-0.7
Total Stockholder Equity	0.56	-0.39	-0.82	0.55		-0.59	0.95	0.68	0.85	-0.79	0.92	0.36	0.12	0.7	-0.57	-0.39	-0.54	0.52	0.35	0.6	-0.73	-0.73	0.73	0.37	-0.71	-0.89
Other Liab	0.26	0.65	0.55	0.06	-0.59		-0.75	0.16	-0.39	0.52	-0.28	0.47	0.43	0.07	-0.01	0.93	0.68	0.14	0.15	0.02	0.03	0.77	-0.63	0.47	0.8	0.28
Net Tangible Assets	0.29	-0.58	-0.78	0.37	0.95	-0.75		0.47	0.74	-0.78	0.78	0.07	-0.13	0.54	-0.47	-0.54	-0.68	0.3	0.15	0.36	-0.48	-0.82	0.84	0.13	-0.82	-0.78
Property Plant And Equipment Net	0.86	0.02	-0.62	0.78	0.68	0.16	0.47		0.79	-0.49	0.9	0.89	0.4	0.97	-0.79	0.28	-0.13	0.63	0.71	0.74	-0.85	-0.27	0.38	0.93	-0.26	-0.88
Current Deferred Revenue	0.53	-0.45	-0.9	0.77	0.85	-0.39	0.74	0.79		-0.71	0.92	0.56	-0.04	0.81	-0.69	-0.36	-0.59	0.29	0.77	0.61	-0.73	-0.74	0.66	0.61	-0.75	-0.91
Net Debt	-0.36	0.63	0.47	-0.74	-0.79	0.52	-0.78	-0.49	-0.71		-0.67	-0.27	-0.03	-0.45	0.12	0.41	0.74	-0.34	-0.33	-0.27	0.42	0.79	-0.52	-0.24	0.7	0.66
Retained Earnings	0.76	-0.19	-0.83	0.7	0.92	-0.28	0.78	0.9	0.92	-0.67		0.67	0.25	0.9	-0.77	-0.11	-0.37	0.6	0.61	0.77	-0.88	-0.57	0.63	0.7	-0.55	-0.97
Accounts Payable	0.9	0.34	-0.31	0.76	0.36	0.47	0.07	0.89	0.56	-0.27	0.67		0.63	0.78	-0.56	0.5	0.2	0.68	0.74	0.74	-0.81	0.06	-0.06	0.94	0.11	-0.63
Cash	0.8	0.74	0.19	0.2	0.12	0.43	-0.13	0.4	-0.04	-0.03	0.25	0.63		0.22	-0.02	0.6	0.64	0.91	0.01	0.58	-0.6	0.46	-0.46	0.4	0.58	-0.16
Non Current Assets Total	0.75	-0.1	-0.72	0.7	0.7	0.07	0.54	0.97	0.81	-0.45	0.9	0.78	0.22		-0.89	0.2	-0.21	0.49	0.69	0.65	-0.77	-0.33	0.51	0.89	-0.37	-0.92
Non Currrent Assets Other	-0.54	0.01	0.79	-0.36	-0.57	-0.01	-0.47	-0.79	-0.69	0.12	-0.77	-0.56	-0.02	-0.89		-0.11	0.1	-0.28	-0.57	-0.61	0.66	0.24	-0.58	-0.73	0.35	0.79
Other Assets	0.44	0.71	0.48	0.03	-0.39	0.93	-0.54	0.28	-0.36	0.41	-0.11	0.5	0.6	0.2	-0.11		0.71	0.39	-0.01	0.13	-0.1	0.75	-0.51	0.5	0.79	0.12
Long Term Debt	0.24	0.95	0.5	-0.43	-0.54	0.68	-0.68	-0.13	-0.59	0.74	-0.37	0.2	0.64	-0.21	0.1	0.71		0.34	-0.27	0.13	-0.06	0.94	-0.75	0.07	0.92	0.39
Cash And Short Term Investments	0.92	0.48	-0.17	0.37	0.52	0.14	0.3	0.63	0.29	-0.34	0.6	0.68	0.91	0.49	-0.28	0.39	0.34		0.12	0.73	-0.8	0.11	-0.08	0.51	0.21	-0.52
Net Receivables	0.47	-0.16	-0.57	0.81	0.35	0.15	0.15	0.71	0.77	-0.33	0.61	0.74	0.01	0.69	-0.57	-0.01	-0.27	0.12		0.52	-0.58	-0.34	0.21	0.78	-0.36	-0.61
Good Will	0.84	0.38	-0.53	0.45	0.6	0.02	0.36	0.74	0.61	-0.27	0.77	0.74	0.58	0.65	-0.61	0.13	0.13	0.73	0.52		-0.95	-0.19	0.27	0.65	-0.07	-0.61
Common Stock Shares Outstanding	-0.92	-0.25	0.64	-0.59	-0.73	0.03	-0.48	-0.85	-0.73	0.42	-0.88	-0.81	-0.6	-0.77	0.66	-0.1	-0.06	-0.8	-0.58	-0.95		0.23	-0.27	-0.72	0.17	0.79
Non Current Liabilities Total	0.02	0.81	0.67	-0.47	-0.73	0.77	-0.82	-0.27	-0.74	0.79	-0.57	0.06	0.46	-0.33	0.24	0.75	0.94	0.11	-0.34	-0.19	0.23		-0.83	-0.02	0.94	0.54
Capital Lease Obligations	0.04	-0.62	-0.75	0.23	0.73	-0.63	0.84	0.38	0.66	-0.52	0.63	-0.06	-0.46	0.51	-0.58	-0.51	-0.75	-0.08	0.21	0.27	-0.27	-0.83		0.14	-0.82	-0.61
Inventory	0.8	0.19	-0.41	0.74	0.37	0.47	0.13	0.93	0.61	-0.24	0.7	0.94	0.4	0.89	-0.73	0.5	0.07	0.51	0.78	0.65	-0.72	-0.02	0.14		-0.01	-0.68
Other Current Assets	0.1	0.87	0.78	-0.4	-0.71	0.8	-0.82	-0.26	-0.75	0.7	-0.55	0.11	0.58	-0.37	0.35	0.79	0.92	0.21	-0.36	-0.07	0.17	0.94	-0.82	-0.01		0.6
Other Stockholder Equity	-0.69	0.29	0.85	-0.7	-0.89	0.28	-0.78	-0.88	-0.91	0.66	-0.97	-0.63	-0.16	-0.92	0.79	0.12	0.39	-0.52	-0.61	-0.61	0.79	0.54	-0.61	-0.68	0.6

Click cells to compare fundamentals

Biora Therapeutics Account Relationship Matchups

Biora Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	101.7M	154.4M	108.8M	53.5M	31.2M	29.7M
Short Long Term Debt Total	73.4M	162.3M	126.4M	127.8M	47.4M	45.1M
Other Current Liab	6.0M	54.6M	52.6M	18.8M	56.7M	35.5M
Total Current Liabilities	100.3M	72.7M	61.6M	23.3M	63.0M	53.2M
Total Stockholder Equity	(83.9M)	(107.0M)	(85.0M)	(102.3M)	(101.4M)	(106.5M)
Property Plant And Equipment Net	15.9M	17.8M	4.0M	3.1M	2.8M	2.6M
Current Deferred Revenue	77.6M	378K	301K	47K	542K	514.9K
Net Debt	40.3M	70.2M	38.0M	97.3M	32.2M	55.3M
Retained Earnings	(348.5M)	(541.3M)	(788.7M)	(826.8M)	(951.0M)	(998.5M)
Accounts Payable	15.8M	17.4M	8.7M	3.6M	2.8M	2.7M
Cash	33.0M	92.1M	88.4M	30.5M	15.2M	14.5M
Non Current Assets Total	27.1M	28.1M	10.4M	15.4M	12.1M	16.1M
Other Assets	198K	13.9M	326K	1.0	0.9	0.86
Long Term Debt	72.0M	161.7M	126.4M	127.8M	43.7M	80.3M
Cash And Short Term Investments	33.0M	92.1M	88.4M	30.5M	15.2M	14.5M
Net Receivables	22.8M	6.6M	653K	828K	830K	788.5K
Common Stock Shares Outstanding	1.8M	2.2M	3.8M	7.6M	15.8M	16.6M
Liabilities And Stockholders Equity	101.7M	154.4M	108.8M	53.5M	31.2M	29.7M
Non Current Liabilities Total	85.3M	188.8M	132.2M	132.5M	69.7M	125.3M
Capital Lease Obligations	1.1M	358K	12K	1.5M	1.7M	873.9K
Inventory	10.9M	12.2M	2.1M	2.6M	2.3M	2.2M
Other Current Assets	1.4M	15.4M	9.4M	6.8M	3.0M	2.9M
Other Stockholder Equity	264.6M	434.2M	703.6M	724.5M	849.5M	565.0M
Total Liab	185.6M	261.4M	193.8M	155.8M	132.6M	144.4M
Net Invested Capital	(11.6M)	55.0M	41.4M	25.5M	(55.7M)	(52.9M)
Short Long Term Debt	241K	271K	12K	2.0M	2.3M	2.4M
Total Current Assets	74.6M	126.3M	98.4M	38.1M	19.1M	18.1M
Capital Stock	38K	59K	146K	8K	25K	40.5K
Non Current Liabilities Other	654K	1.6M	5.6M	4.1M	2.2M	2.7M
Net Working Capital	(25.7M)	53.7M	36.8M	14.8M	(43.9M)	(41.7M)
Short Term Debt	968K	338K	24K	893K	2.9M	3.0M

Pair Trading with Biora Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biora Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biora Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Biora Stock

0.81	FDMT	4D Molecular Therapeutics	Pair Corr
0.87	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.95	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr

Moving against Biora Stock

0.91	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.81	NAMS	NewAmsterdam Pharma	Pair Corr
0.62	PMVP	Pmv Pharmaceuticals	Pair Corr
0.6	PHVS	Pharvaris BV	Pair Corr
0.4	ESLAW	Estrella Immunopharma	Pair Corr

The ability to find closely correlated positions to Biora Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biora Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biora Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biora Therapeutics to buy it.

The correlation of Biora Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biora Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biora Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Biora Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Biora Stock Analysis

When running Biora Therapeutics' price analysis, check to measure Biora Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biora Therapeutics is operating at the current time. Most of Biora Therapeutics' value examination focuses on studying past and present price action to predict the probability of Biora Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biora Therapeutics' price. Additionally, you may evaluate how the addition of Biora Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biora Historical Balance Sheet

Biora Therapeutics Inventory

2.23 Million

About Biora Balance Sheet Analysis

Biora Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Biora Therapeutics balance sheet Correlations

Biora Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Biora Therapeutics balance sheet Accounts

Pair Trading with Biora Therapeutics

Moving together with Biora Stock

Moving against Biora Stock

Additional Tools for Biora Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 0.97	Property Plant And Equipment Net
Long Term Debt	+ 0.95	Short Long Term Debt Total
Net Tangible Assets	+ 0.95	Total Stockholder Equity
Inventory	+ 0.94	Accounts Payable
Non Current Liabilities Total	+ 0.94	Long Term Debt
Other Current Assets	+ 0.94	Non Current Liabilities Total

Other Stockholder Equity	- 0.97	Retained Earnings
Common Stock Shares Outstanding	- 0.95	Good Will
Other Stockholder Equity	- 0.92	Non Current Assets Total
Common Stock Shares Outstanding	- 0.92	Total Assets
Other Stockholder Equity	- 0.91	Current Deferred Revenue
Current Deferred Revenue	- 0.9	Other Current Liab